Chemotherapy Induced Anemia Market is segmented By Application (Cardiac Surgery, General Intensive Care & Emergency Medicine, Thoracic Surgery & Pulmonology, Oncology & P ....
Market Size in USD
CAGR6.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.1% |
Market Concentration | Medium |
Major Players | Amgen Inc., Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. |
The chemotherapy induced anemia market is estimated to be valued at USD 2.65 Bn in 2024 and is expected to reach USD 4.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The high prevalence of cancer patients undergoing chemotherapy as the primary line of treatment is expected to drive the demand for chemotherapy induced anemia drugs and therapeutics.